Analysis of HIV medication adherence in relation to person and treatment characteristics using hierarchical linear modeling

AIDS Patient Care and STDs

Volumn 22, Issue 4, 2008, Pages 323-335

  Halkitis, Perry ^a   Palamar, Joseph ^a   Mukherjee, Preetika ^a  

^a NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; AGE; AGED; ARTICLE; DRUG USE; ETHNICITY; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MALE HOMOSEXUAL; RACE DIFFERENCE; STATISTICAL MODEL;

ADULT; AGE FACTORS; AGED; ANTI-HIV AGENTS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HOMOSEXUALITY, MALE; HUMANS; INTERVIEWS AS TOPIC; LINEAR MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PERSONALITY ASSESSMENT; SUBSTANCE-RELATED DISORDERS;

EID: 42449104417     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2007.0122     Document Type: Article

References (71)

1. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
2. Haubrich RH, Little S, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting antivirologic and immunologic response. AIDS 1999;13:1099-1107.
3. Wood E, Hogg RS, Yip B, et al. The impact of adherence on CD4 cell count responses among HIV-infected patients. JAIDS 2004;35:261-268.
4. Bangsberg DR, Acosta EP, Gupta R, et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 2006;20:223-231.
5. Pillay D. The emergence and epidemiology of resistance in the nucleoside-experienced HIV-infected population. Antiviral Ther 2001;6:15-24.
6. Condra JH. Resistance to HIV protease inhibitors. Haemophilia 1998;4:610-615.
7. Kalichman SC, Rompa D. HIV treatment adherence and unprotected sex practices in people receiving antiretroviral therapy. Sex Transm Infect 2003;79:59-61.
8. Kozal MJ, Amico KR, Chiarella J, et al. HIV drug resistance and HIV transmission risk behaviors among active injection drug users. JAIDS 2005;40:106-109.
9. Borrell-Carrio F, Suchman AL, Epstein RM. The biopsychosocial model 25 years later: Principles, practice, and scientific inquiry. Ann Fam Med 2004;2:576-582.
10. Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis 2002;34:1115-1121.
11. Johnson MO, Catz SL, Remien RH, et al. Theory-guided, empirically supported avenues for intervention on HIV medication nonadherence: Findings from the Healthy Living Project. AIDS Patient Care STDs 2003;17:645-656.
12. Kleeberger CA, Phair JP, Strathdee SA, et al. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Trial. JAIDS 2001;26:82-92.
13. Siegel K, Karus D, Schrimshaw EW. Racial differences in attitudes toward protease inhibitors among older HIV-infected men. AIDS Care 2000;12:423-434.
14. Israelski D, Gore-Felton C, Power R, Wood MJ, Koopman C. Sociodemographic characteristics associated with medical appointment adherence among HIV-seropositive patients seeking treatment in a county outpatient facility. Prev Med 2001;33:470-475.
15. Halkitis PN, Parsons JT, Wolitski RJ, Remien RH. Characteristics of HIV antiretroviral treatments, access and adherence in an ethnically diverse sample of men who have sex with men. AIDS Care 2003;15:89-102.
16. Fiscella K, Franks P, Doescher MP, Saver BG. Disparities in health care by race, ethnicity, and language among the insured. Med Care 2002;40:52-59.
17. Blendon RJ, Aiken LH, Freeman HE, Corey CR. Access to medical care for black and white Americans: A matter of continuing concern. JAMA 1989;261:278-281.
18. van Servellen GV, Change B, Garcia L, Lombardi E. Individual and system level factors associated with treatment nonadherence in human immunodeficiency virus-infected men and women. AIDS Patient Care STDs 2002;16:269-281.
19. Nemes MIB, Carvalho HB, Souza MFM. Antiretroviral therapy adherence in Brazil. AIDS 2004;18:S15-S20.
20. Wood E, Montaner JS, Chan K, et al. Socioeconomic status, access to triple therapy, and survival from HIV-disease since 1996. AIDS 2002;16:2065-2072.
21. Carballo E, Cadarso-Suarez C, Carrera I, et al. Assessing relationships between health-related quality of life and adherence to antiretroviral therapy. Qual Life Res 2004;13:587-599.
22. Deloria-Knoll M, Chmiel JS, Moorman AC, et al. Factors related to and consequences of adherence to antiretroviral therapy in an ambulatory HIV-infected patient cohort. AIDS Patient Care 2004;18:721-727.
23. Stirratt MJ, Remien RH, Smith A, et al. The role of HIV serostatus disclosure in antiretroviral medication adherence. AIDS Behav 2006;10:483-493.
24. Peretti-Watel P, Spire B, Schiltz MA, et al. Vulnerability, unsafe sex and non-adherence to HAART: Evidence from a large sample of French HIV/AIDS outpatients. Soc Sci Med 2006;62:2420-2433.
25. Wagner GJ, Remien RH, Carballo-Dieguez A, Dolezal C. Correlates of adherence to combination antiretroviral therapy among members of HIV-positive mixed status couples. AIDS Care 2002;14:105-109.
26. Holt R, Court P, Vedhara K, et al. The role of disclosure in coping with HIV infection. AIDS Care 1998;10:49-60.
27. Klitzman RL, Kirshenbaum B, Dodge B, et al. Intricacies and inter-relationships between HIV disclosure and HAART: A qualitative study. AIDS Care 2004;16:628-640.
28. Hinkin CH, Hardy DJ, Mason KI, et al. Medication adherence in HIV-infected adults: Effect of patient age, cognitive status, and substance abuse. AIDS 2004;18:S19-S25.
29. Maggiolo F, Ripamonti D, Arici C, et al. Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients. HIV Clin Trials 2002;3:371-378.
30. Puigventos F, Riera M, Delibes C, et al. Adherence to antiretroviral drug therapy: A systematic review. Med Clin 2002;119:130-137.
31. Kastrissios H, Suarez JR, Katzenstein D, et al. Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial. AIDS 1998;12:2295-2303.
32. Wellons MF, Sanders L, Edwards LJ, et al. HIV infection: Treatment outcomes in older and younger adults. J Am Geriat Soc 2002;50:603-607.
33. Wutoh AK, Brown CM, Kumoji EK, et al. Antiretroviral adherence and use of alternative therapies among older HIV-infected adults. J Natl Med Assoc 2001;93:243-250.
34. Goodkin K, Shapshak P, Asthana D, et al. Older age and plasma viral load in HIV-1 infection. AIDS 2004;18:S87-S98.
35. Halkitis PN, Kutnick AH, Slater S. The social realities of adherence to protease inhibitor regimens: Substance use, health care and psychological states. J Health Psychol 2005;10:545-558.
36. Turner CF, Ku L, Rogers SM, et al. Adolescent sexual behavior, drug use, and violence: Increased reporting with computer survey technology. Science 1998;280:867-873.
37. Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS 1999;13:1099-1107.
38. Bondi MW, Drake AI, Grand I. Verbal learning and memory in alcohol abusers and poly-substance abusers with concurrent alcohol abuse. J Int Neuropsychol Soc 1998;4:319-328.
39. Waldrop-Valverde D, Ownby RL, Wilkie FL, et al. Neurocognitive aspects of medication adherence in HIV-positive in injecting drug users. AIDS Behav 2006;10:287-297.
40. Witteveen E, van Ameijden EJC. Drug users and HIVcombination therapy (HAART): Factors which impede or facilitate adherence. Subst Use Misuse 2002;37:1905-1925.
41. Murphy DA, Roberts KJ, Martine DJ, Marelich W, Hoffman D. Barriers to antiretroviral adherence among HIV-infected adults. AIDS Patient Care STDs 2000;14:47-58.
42. Peretti-Watel P, Spire B, Lert F, Obadia Y, VESPA Group. Drug use patterns and adherence to treatment among HIV-positive patients: Evidence from a large sample of French outpatients. Drug Alcohol Depend 2006;82(suppl 1):S71-S79.
43. Braithwaite RS, McGinnis KA, Conigliaro J, et al. A temporal and dose-response association between alcohol consumption and medication adherence among veterans in care. Alcohol Clin Exp Res 2005;29:1190-1197.
44. Back DJ, Burger DM, Flexner CW, Gerber JG. The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors: Implications for once-daily dosing. JAIDS 2005;39:S1-S23.
45. Portsmouth SD, Osorio J, McCormick K, Gazzard BG, Moyle GJ. Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: A 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules. HIV Med 2005;6:185-190.
46. Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001;134:968-977.
47. Holzemer WL, Bakken S, Portillo CJ, Grimes R, Welch J. Testing a nurse-tailored HIV medication adherence intervention. Nurs Res 2006;55:189-197.
48. de Bruin M, Hospers HJ, van den Borne HW, Kok G, Prins JM. Theory- and evidence-based intervention to improve adherence to antiretroviral therapy among HIV-infected patients in the Netherlands: A pilot study. AIDS Patient Care STDs 2005;19:384-394.
49. Rathbun RC, Farmer KC, Stephens JR, Lockhart SM. Impact of an adherence clinic on behavioral outcomes and virologic response in treatment of HIV infection: A prospective, randomized, controlled pilot study. Clin Ther 2005;27:199-209.
50. Wagner GJ. Predictors of antiretroviral adherence as measured by self-report, electronic monitoring, and medication diaries. AIDS Patient Care STDs 2002;16:599-608.
51. Pinheiro CA, de-Carvalho-Leite JC, Drachler ML, Silveira VL. Factors associated with adherence to antiretroviral therapy in HIV/AIDS patients: A cross-sectional study in Southern Brazil. Brazil J Med Bio Res 2002;35:1173-1181.
52. Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side-effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. JAIDS 2001;28:445-449.
53. Wilson KJ, Doxanakis A, Fairley CK. Predictors for non-adherence to antiretroviral therapy. Sex Health 2004;1:251-257.
54. Knafl GJ, Fennie KP, Bova C, Dieckhaus K, Williams AB. Electronic monitoring device event modeling on an individual-subject basis using adaptive Poisson Regression. Stat Med 2004;23:783-801.
55. Ickovics JR, Meisler AW. Adherence in AIDS clinical trials: A framework for clinical research and clinical care. J Clin Epidemiol 1997;50:385-391.
56. Watters JK, Biernacki P. Targeted sampling: Options for the study of hidden populations. Soc Problems 1989;36:416-430.
57. Skinner HA. The drug abuse screening test. Addict Behav 1982;7:363-371.
58. Kruse W, Rampmaier J, Ullrich G, Weber E. Patterns of drug compliance with medications to be taken once and twice daily assessed by continuous electronic monitoring in primary care. Int J Clin Pharm Ther 1994;32:452-457.
59. Wagner GJ, Rabkin JG. Measuring medication adherence: Are missed doses reported more accurately then perfect adherence? AIDS Care 2000;12:405-408.
60. Hill Z, Kendall C, Fernandez M. Patterns of adherence to antiretrovirals: Why adherence has no simple measure. AIDS Patient Care STDs 2003;17:519-525.
61. Bryk SW, Raudenbush AS, eds. Hierarchical Linear Models: Applications and Data Analysis Methods. Thousand Oaks, CA: Sage Publications, Inc., 1992.
62. Bryk SW, Raudenbush AS. Examining correlates of diversity. J Edu Stat 1987;12:241-269.
63. Strenio JLF, Weisberg HI, Bryk AS. Empirical Bayes estimation of individual growth curves parameters and their relationship to covariates. Biometrics 1983;39:71-86.
64. Ferguson TF, Stewart KE, Funkhouser E, et al. Patient-perceived barriers to antiretroviral adherence: Associations with race. AIDS Care 2002;14:607-617.
65. Wynn GH, Cozza KL, Zapor MJ, Wortmann GW, Armstrong SC. Antiretrovirals, Part III: Antiretrovirals and drugs of abuse. Psychosomatics 2005;46:79-87.
66. Antoniou T, Tseng AL. Interactions between recreational drugs and antiretroviral agents. Ann Pharmacother 2002;36:1598-1613.
67. Harrington RD, Woodward JA, Hooton TM, Horn JR. Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and γ-hydroxybutyrate. Arch Intern Med 1999;159:2221-2224.
68. Joy JE, Watson SJ Jr., Benson JA Jr., eds. The medical value of marijuana and related substances. In: Marijuana and Medicine: Assessing the Science Base. Washington, DC: National Academy Press, 1999:137-191.
69. Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy. Neurology 2007;68:515-521.
70. Ware NC, Wyatt MA, Tugenberg T. Adherence, stereotyping and unequal HIV treatment for active users of illegal drugs. Soc Sci Med 2005;61:565-576.
71. Miller WR, Rollnick S. Talking oneself into change: Motivational interviewing, stages of change, and therapeutic process. J Cog Psychother 2004;18:299-308.